Research on molecular targeted therapy for tumors is increasing, and new targeted therapeutic agents are emerging. Some small molecules can be used as novel therapeutic agents. Combined with nanotechnology, smart drugs can actively target tumors by binding to corresponding receptors on tumor cells through interactions with phenotype-specific ligands conjugated to the delivery vehicle. Additionally, binding to certain receptors can trigger internalization and help avoid the development of resistance mechanisms.

The rationale behind targeting via small molecules is to affect the molecular biology underlying tumorigenesis by modulating the activity of protein targets. These targets mainly include enzymes and receptors. Small molecules acting on receptors can be classified as agonists or antagonists. Small molecules that act as enzyme inhibitors reduce their catalytic activity by binding to them.

These molecules can bind to targets highly expressed on cancer cell surfaces and be targeted during drug delivery. For example, folic acid (folates) can be used. Cancer and embryonic cells preferentially use the folate receptor (FR), which has a high affinity for folic acid (K_d = 110nM) and can uptake folic acid via receptor-mediated endocytosis. This makes folic acid an attractive ligand for active targeting.

Another available option is the prostate-specific membrane antigen (PSMA) inhibitor EC1169. PSMA is a surface glycoprotein associated with high-grade and metastatic prostate cancer. It undergoes rapid internalization upon binding to mAbs or other ligands. Additionally, there is the glucose transporter targeting agent glufosfamide (D-19575). Cancer cells depend heavily on glucose and glycolysis for survival and express glucose transporters.

To support researchers to develop highly precise drug delivery systems, CD Bioparticles now offers various custom services for bio-targeted small molecules conjugated magnetic nanoparticles, including the synthesis of basic magnetic particles, the functionalization and conjugation of custom small molecules, and basic characterization. These particles possess several key properties, including active targeting, easy internalization, reduced drug resistance, and an enhanced permeability and retention (EPR) effect. In addition, they can be applied in diverse fields, such as biological imaging, biosensing, chemotherapy drug delivery, and synergy with other therapies like magnetic hyperthermia.

Clients can specify requirements for particle diameter, component, functionalization type and density, desired bio-targeted small molecule, quantity, format, and QC materials. For more information on CD Bioparticles' custom Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles synthesis services, please visit https://www.cd-bioparticles.com/services/bio-targeted-small-molecules-conjugated-magnetic-nanoparticles.html.

Exosomes are extracellular vesicles secreted by human cells that exhibit biofilm characteristics. They have a particle size of 30-150 nanometers. All relevant cells in the body secrete exosomes of the corresponding cell type. These extracellular vesicles have a phospholipid bilayer structure and can carry important biological information, such as proteins, nucleic acids (e.g., microRNA and long non-coding RNA), and lipids. These extracellular vesicles, composed of cell membranes, can attach to target cells through surface adhesion proteins and carrier ligands, such as tetrapeptides, integrins, CD11b, and CD18 receptors, and deliver their payloads. Several studies have shown that, depending on their properties and origin, extracellular vesicles, such as exosomes, have specific cell tropism and can be used to target diseased tissues or organs.

Exosomes are derived from endosomes. These membranous vesicles are released outside the cell by fusing with the plasma membrane via a multivesicular body (MVB). They contain a variety of biomolecules, including proteins, nucleic acids, and phospholipids. Exosomes have many biological functions and serve as an important pathway for the intercellular exchange of substances and signals. Exosomes play a corresponding role in the development of many known diseases and participate in various physiological and pathological processes.

Exosome carriers offer the benefits of both cellular drug delivery and nanotechnology. As a new type of drug delivery carrier with natural properties, they can cross the biological barriers of the human body. Therefore, using exosomes as carriers enables effective and safe drug delivery. They can be delivered to all major systems of the human body, making them a viable and effective method of treating diseases with a promising future.

Exosomes derived from animal, plant, and microbial sources exhibit certain biological activities, such as anti-inflammatory, antioxidant, whitening, and anticancer properties. They can be used in the research of functional foods, nutraceuticals, cosmetics, and cancer therapies. CD Bioparticles produces and supplies high-purity exosomes from animal, plant, and microbial sources, including the Exosomes from MCF-7 (CDE23-001), Exosomes from MDA-MB-231 (CDE23-002), and Exosomes from PCS-500-011 (CDE23-008). For instance, the Exosomes from HEK293 Cells (CDE23-015) are frozen exosomes (>110^6) from the HEK293 human embryonic kidney cell line. They can be used as an exosome standard in the evaluation of biomarkers.

CD Bioparticles is proud to provide a comprehensive range of high-purity exosomes, ensuring researchers have access to the highest quality materials for their critical work. To learn more about solutions for exosome research, please visit https://www.cd-bioparticles.net/purified-exosomes.